🚀
Enjoy a 7-Day Free Trial Thru May 03, 2024!
✨
Sign Up
Login
Free Sign-up
Login
7-Day Free Trial
Home
Homepage
Membership Levels
About Us
General Discussion
Complete Stock List
The book
Membership Data Coverage
Founder's Message
Free Trial
Referral Program
Partner Program
GuruFocus Podcast
Screeners
GuruFocus Screeners
All-In-One Screener
Ben Graham Lost Formula
Canadian Faster Growers
CEO Buys
CEO Buys after Price Drop > 20%
Dividend Kings 2023
Dividend Aristocrats 2023
Dividend Growth Portfolio
Dividend Income Portfolio
Fast Growers
Good Companies
Hedge Fund Guru Top 10 Aggregated
High Quality
High Quality Low Capex w ROE ROC min
High Quality & Low Capex
High Yield Insider Buys
Historical High Dividend Yields
International Gurus' Top Holdings
James Montier Short Screen
Margin Decliners
Mega Caps
Peter Lynch & Warren Buffett
Peter Lynch Growth w Lower Valuation
Peter Lynch S&L Traded Below Book
PFCF Screener
Piotroski Score Screener
Predictable Growth Companies
Profitable predictable margin expanders
Stocks Sold w less Cash
The Stalwarts
My Screeners
Create My Screener
Value Screens
Stock Ideas
All-In-One Screener
S&P 500 Map
S&P 500 Bubble
S&P 500 Aggregate
Buffett-Munger Screener
Industry Overview
Undervalued Predictable
Benjamin Graham Net-Net
52-week/3Y/5Y Lows
52-week/3Y/5Y Highs
Magic Formula(Greenblatt)
Dividend Stocks
Peter Lynch Screen
S&P500 Grid
Predictable Companies
Spin Off List
Merger and Acquisition List
Historical Low P/B List
Historical Low P/S List
High Short Interest
Upcoming Special Dividends
Delisted Stocks
Model Portfolios
Performances Overview
Most Broadly Held Portfolio
Most Weighted Portfolio
Buffett-Munger Top 25
GF Score <= 100 Top 25
Top 25 Undervalued Predictable
Top 25 52-week Low Predictable
Top 25 Historical Low P/S
Stock Comparison
Airline Stocks
Artificial Intelligence Stocks
Bank Stocks
Biotech Stocks
Blockchain Stocks
Chinese Stocks
Dividend Stocks
EV Stocks
Growth Stocks
Oil Stocks
Value Stocks
Virtual Reality Stocks
Compare More Stocks…
Gurus
Guru Trades
Latest Guru Picks
Real Time Picks
Guru Portfolio
Score Board
Mutual Funds
Top 10 Holdings
Sector Picks
International Picks
Aggregated Portfolio
Consensus Picks
Guru Bargains
Hot Picks
Download Guru Portfolios
Industry Trends
Geographic Trend
ETFs
Options Holdings
European Shorting
Guru Lists
Complete Guru List
Warren Buffett
Bill Gates
Mohnish Pabrai
Carl Icahn
George Soros
David Tepper
Seth Klarman
Bill Ackman
Joel Greenblatt
Charlie Munger
Michael Price
Julian Robertson
Chuck Akre
David Einhorn
Tom Gayner
My Guru Lists
Insiders
Insider Trading Tracker
Real-Time Insider Picks
CEO Buys/Sells
CFO Buys/Sells
Insider Trends
Insider Cluster
Guru + Insider Double Buys
Triple Buys/Sells
Chinese Insider
German Insider
Complete Insider List
Politician Trading Tracker
Real-Time Politician Picks
Complete Politician List
Nancy Pelosi
Mitch Mcconnell
Tommy Tuberville
Josh Gottheimer
Kevin Hern
Thomas R. Carper
Susie Lee
Lois Frankel
Market
US Market Valuation
Buffett Indicator
U.S. Treasury Yield Curve
U.S. Inflation Rate
Presidential Cycle and Stock Market
Shiller P/E
Shiller P/E by Sectors
GF Value for S&P 500 Index
Fed Net Liquidity
Buffett Assets Allocation
Latest IPOs
Global Market Valuation
Global Market Overview
USA
China
Japan
India
Canada
UK
France
Germany
Brazil
Australia
More...
Economic Indicators
Economic Indicators Overview
The Dow Jones Industrial Average (DJIA)
SP 500 Index
Nasdaq Composite Index
Gross Domestic Product (GDP)
Shiller PE
Ratio of Wilshire 5000 over GNP
Civilian Unemployment Rate
Russell 2000 Index
CBOE Volatility Index (VIX)
Total Nonfarm Payrolls: All Employees
More...
Sector & Industry Performance
Global Industry Overview
USA
Asia
Europe
Canada
UK/Ireland
Oceania
Latin America
Africa
India/Pakistan
Articles
Articles
Editors' Picks
Stock Market News
Q&A with Gurus
Guru Stock Picks
Insider Transaction
Earning Reports
CEO Shareholder Letters
Podcast
Earnings Call Transcripts
Software Stock News
Biotechnology Stock News
Hardware Stock News
Banks Stock News
Metals & Mining Stock News
Drug Manufacturers Stock News
All Articles
Submit Articles
Submit Article Online
Contributor Guidelines
Tools
Model Portfolios
All-In-One Screener
Data Batch Download
Guru Portfolio Download
Insider Data Download
Excel Add-In
Google Sheets Add-On
API
Manual of Stocks
DCF Calculator
WACC Calculator
Interactive Chart
Maps
Fund Letters Archive
Stock Comparison Table
Mobile App
Discussion Board
GuruGPT
Financial Calendar
Embed Widgets
Stock Market Holidays
Discussion
Discussion Board
GuruFocus Discord
ETF
Data
Pricing
Tutorials
Tutorials
Financial Glossary
FAQ
Change Log
Contact Us
Support
Chat Support
Create a ticket
Book Demo
User Engagement Meeting
469-248-6885
Status
Take Survey
Ask the community in Discord
Subscribe
Free Trial
Group Subscription
Refer a Friend and Earn One Month of Free Membership
GURUFOCUS.COM
STOCK LIST
Healthcare
Biotechnology
Instil Bio Inc (NAS:TIL)
News
Instil Bio Inc
1
NAS
:TIL (USA) Â
$ 10.40
-0.31 (-2.89%)
10:08 PM EST
P/E:
At Loss
P/B:
0.30
Market Cap:
$ 67.64M
Enterprise V:
$ 5.36M
Volume:
21.04K
Avg Vol (2M):
13.07K
Warning! GuruFocus detected 4 Severe warning signs with TIL.
Try a 7-Day Free Trial
to check it out.
Volume:
21.04K
Market Cap $:
67.64M
PE Ratio:
At Loss
Avg Vol (2M):
13.07K
Enterprise Value $:
5.36M
PB Ratio:
0.30
Alerts
Website
SEC Filings
Stock PDF
Dataset
Financial Download
Manual of Stocks™
Compare
0
Summary
30-Y Financials
Estimates
DCF
Dividend
Guru Trades
Insider
Interactive Chart
Filings
Transcripts
News
Compare
Stock PDF
Ownership
Operating
Checklist
Vote
Definitions
Instil Bio Inc (NAS:TIL) Stock News, Headlines & Updates
Instil Bio Inc Stock News from GuruFocus
Total 28
1
Feb 09, 2024
Instil Bio Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
GuruFocus Research
•
12:06am
Nov 06, 2023
Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting
Marketwired
•
6:00am
Aug 14, 2023
Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Marketwired
•
7:00am
Jun 26, 2023
Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference
Marketwired
•
4:00pm
Jan 31, 2023
Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. Site
Stock market mentor
•
4:00pm
Dec 30, 2022
INSTIL BIO ALERT: Bragar Eagel & Squire, P.C. is Investigating Instil Bio, Inc. on Behalf of Instil Bio Stockholders and Encourages Investors to Contact the Firm
Tiesvg
•
9:00pm
Dec 08, 2022
Instil Bio Announces Prioritization of Genetically Engineered CoStAR-TIL Program with ITIL-306 in Advanced Solid Tumors and Reduction in Workforce
Value_Insider
•
6:00am
Nov 07, 2022
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Instil Bio, Inc. - TIL
Value_Insider
•
4:01pm
Nov 03, 2022
Instil Bio, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses
Value_Insider
•
2:00pm
Nov 01, 2022
TIL EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Instil Bio, Inc. Investors to Inquire About Securities Class Action Investigation – TIL
Value_Insider
•
5:00pm
Oct 31, 2022
Instil Bio Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
Value_Insider
•
9:00am
Instil Bio Announces Voluntary Pause of Enrollment in Ongoing Clinical Trials Related to Manufacturing
Value_Insider
•
6:00am
Oct 18, 2022
Instil Bio Announces First Patient Dosed with ITIL-306, our First Engineered TIL Therapy Using the CoStAR Platform Targeting Folate Receptor Alpha (FR?), in Non-Small Cell Lung Cancer
Value_Insider
•
6:00am
Jul 07, 2022
Instil Bio to Present Novel TIL Analytics at American Society of Gene and Cell Therapy (ASGCT)
GuruFocusNews
•
7:12am
Jun 16, 2022
Instil Bio Announces IND Clearance of First CoStAR-TIL program, ITIL-306, Designed to Enhance Activity in the Tumor Microenvironment
GuruFocusNews
•
6:15am
Jun 06, 2022
Instil Bio Announces IND Clearance of First CoStAR-TIL program, ITIL-306, Designed to Enhance Activity in the Tumor Microenvironment
GuruFocusNews
•
6:13am
May 28, 2022
Instil Bio to Present Novel TIL Analytics at American Society of Gene and Cell Therapy (ASGCT)
GuruFocusNews
•
6:08am
May 27, 2022
Instil Bio Announces IND Clearance of First CoStAR-TIL program, ITIL-306, Designed to Enhance Activity in the Tumor Microenvironment
GuruFocusNews
•
6:13am
May 18, 2022
Instil Bio to Present Novel TIL Analytics at American Society of Gene and Cell Therapy (ASGCT)
GuruFocusNews
•
6:07am
May 16, 2022
Instil Bio Reports First Quarter 2022 Financial Results and Provides Corporate Update
GuruFocusNews
•
6:29am
Mar 07, 2022
Instil Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
GuruFocusNews
•
6:00am
Mar 02, 2022
Instil Bio to Present at the Cowen 42nd Annual Health Care Conference
GuruFocusNews
•
6:00am
Nov 15, 2021
Instil Bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Don Li2
•
6:00am
Instil Bio Announces Poster Presentations at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Don Li2
•
6:00am
May 18, 2021
CPMG Inc Buys Instil Bio Inc, Sells Sibanye Stillwater, Golden Star Resources, SSR Mining Inc
GuruFocus Research
•
5:38pm
Apr 27, 2021
Instil Bio Receives Orphan Drug Designation for ITIL-168 in Melanoma
Marketwired
•
6:00am
Mar 29, 2021
Weekly CEO Buys Highlight
Joy Hu
•
10:39am
Mar 26, 2021
Instil Bio Inc (TIL) CEO and Chairman Bronson Crouch Bought $9 million of Shares
GuruFocus Research
•
7:15pm
Total 28
1
Show
20
40
60
80
100
No data
Entries
Headlines
Total 0
1
No recent news